// App-Quantinova.ai

1437O_PR : Clinical benefit of randomized controlled trials (RCT) supporting US Food and Drug Administration (FDA) conversion from accelerated to full approval

Researchers

Presenter

  • M. BorrellPuy

Principal Investigators

  • C. MoltoValiente

  • A. OcanaFernandez

  • A.Templeton

  • B.Seruga

  • I.Gich

  • A.Barnadas

  • E.Amir

  • A.Tibau

Medical Centers

  • Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

  • Medical Oncology Department and Translational Research Unit, Complejo Hospitalario Universitario de Albacete, Albacete, Spain

  • Medical Oncology, St. Claraspital AG, Basel, Switzerland

  • Department for Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

  • Pharmacy, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain,

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • Spain

  • Switzerland

  • Slovenia

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved